A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782
This study is recruiting at 17 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Verastem, Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- HonorHealth Research Institute · Scottsdale, AZ
California · 3
- Cedars-Sinai Medical Center · Los Angeles, CA
- START LA · Los Angeles, CA
- Valkyrie Clinical Trials · Los Angeles, CA
Florida · 2
- BRCR Global- Tamarac · Tamarac, FL
- Moffit Cancer Centre · Tampa, FL
Georgia · 1
- Emory Winship Cancer Institute · Atlanta, GA
Illinois · 1
- University of Chicago · Chicago, IL
New Jersey · 1
- START New Jersey · East Brunswick, NJ
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU · New York, NY
North Carolina · 1
- University of North Carolina at Chapel Hill · Chapel Hill, NC
Texas · 2
- START Fort Worth · Fort Worth, TX
- MD Anderson Cancer Center · Houston, TX
Utah · 1
- University of Utah · Salt Lake City, UT
Virginia · 2
- University of Virginia · Charlottesville, VA
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.